Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD123A in Relapsed or Refractory AML
NCT02848248Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Aug 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGN-CD123A in acute myeloid leukemia (AML), sponsored by Seagen Inc. Primary endpoints: Type, incidence, severity, seriousness, and relatedness of adverse events, Type, incidence, and severity of laboratory abnormalities and 1 more. Started Aug 2016; status: terminated.
02
Drugs
SGN-CD123A
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02848248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848248.